Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Axokine: REGN completed enrollment in a U.S. Phase III trial of short-term Axokine therapy. The double-blind, placebo-controlled trial enrolled 300 patients, wh

Regeneron Pharmaceuticals Inc. (REGN), Tarrytown, N.Y.
Product: Axokine
Business:

Read the full 92 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE